These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 8371917

  • 1. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study.
    Alm A, Villumsen J, Törnquist P, Mandahl A, Airaksinen J, Tuulonen A, Marsk A, Resul B, Stjernschantz J.
    Ophthalmology; 1993 Sep; 100(9):1312-6; discussion 1316-7. PubMed ID: 8371917
    [Abstract] [Full Text] [Related]

  • 2. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens.
    Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J.
    Ophthalmology; 1993 Sep; 100(9):1305-11. PubMed ID: 8371916
    [Abstract] [Full Text] [Related]

  • 3. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study.
    Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M.
    Arch Ophthalmol; 1996 Aug; 114(8):929-32. PubMed ID: 8694726
    [Abstract] [Full Text] [Related]

  • 4. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes.
    Ziai N, Dolan JW, Kacere RD, Brubaker RF.
    Arch Ophthalmol; 1993 Oct; 111(10):1351-8. PubMed ID: 8216015
    [Abstract] [Full Text] [Related]

  • 5. Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study.
    Rácz P, Ruzsonyi MR, Nagy ZT, Bito LZ.
    Arch Ophthalmol; 1993 May; 111(5):657-61. PubMed ID: 8489449
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure.
    Rulo AH, Greve EL, Hoyng PF.
    Ophthalmology; 1997 Sep; 104(9):1503-7. PubMed ID: 9307648
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.
    Watson P, Stjernschantz J.
    Ophthalmology; 1996 Jan; 103(1):126-37. PubMed ID: 8628543
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma.
    Rulo AH, Greve EL, Geijssen HC, Hoyng PF.
    Ophthalmology; 1996 Aug; 103(8):1276-82. PubMed ID: 8764799
    [Abstract] [Full Text] [Related]

  • 15. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA, Travoprost Study Group.
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [Abstract] [Full Text] [Related]

  • 16. A correlation between latanoprost-induced conjunctival hyperemia and intraocular pressure-lowering effect.
    Kobayashi H, Kobayashi K.
    J Glaucoma; 2011 Jan; 20(1):3-6. PubMed ID: 20520573
    [Abstract] [Full Text] [Related]

  • 17. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M, Otani S, Kozaki J, Unoki K, Takeuchi M, Minami K, Miyata K.
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [Abstract] [Full Text] [Related]

  • 18. A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure.
    Lusky M, Ticho U, Glovinsky J, Weinberger D, Nesher R, Yassur Y, Melamed S.
    Ophthalmology; 1997 Oct; 104(10):1720-4. PubMed ID: 9331215
    [Abstract] [Full Text] [Related]

  • 19. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.
    Alm A, Stjernschantz J.
    Ophthalmology; 1995 Dec; 102(12):1743-52. PubMed ID: 9098273
    [Abstract] [Full Text] [Related]

  • 20. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
    Bacharach J, Dubiner HB, Levy B, Kopczynski CC, Novack GD, AR-13324-CS202 Study Group.
    Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.